Skip to Main Content

We’re monitoring Thursday’s meeting of the Food and Drug Administration advisory committee that is reviewing the heart-protective data on Vascepa, a drug derived from fish oil that is marketed by Amarin. Check back here often for analysis throughout the day.

Updates will be posted in reverse chronological order.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.